Tucker Carlson Exposes Big Pharma’s Political Payoffs

According to Tucker Carlson, the lobbying efforts of pharmaceutical companies "pay off" because they can influence politicians. He made the statement Thursday on Fox News.

"According to Carlson, the powerful pharmaceutical companies are able to influence the political process in the US. He noted that it's strange that they can advertise their products directly to consumers, since doctors and patients don't usually prescribe drugs."

In the world, the US is one of only two countries that allow the direct marketing of prescription drugs to consumers, Carlson noted.

"According to Carlson, it's no surprise that pharmaceutical companies spend a lot of money lobbying Congress. They do it due to the "extraordinary deal" they can get with politicians."

"The government purchases billions of dollars worth of pharmaceutical products, and in some cases, they force consumers to use them. Sometimes, these products work, and sometimes they don't. However, no matter how the products can hurt you, politicians will give these companies immunity, allowing them to continue doing business.

Not only does the government buy billions of dollars worth of pharmaceutical products, but they also prevent people from suing them if they cause harm."

During the segment, Carlson repeatedly mentioned Pfizer.

In 2022, Pfizer reported spending over $11 million on lobbying. The company also employed over a hundred lobbyists in a given year.

According to, the pharmaceutical sector spent almost $300 million in 2022 on lobbying.

"Carlson noted that if a company were able to strike a deal with Congress, its profits would be higher."

Pfizer was not able to provide a response to the request for comment made by the DCNF.

The preceding is a summary of an article that originally appeared on Daily Caller.

Written by Staff Reports

Leave a Reply

Your email address will not be published. Required fields are marked *

WATCH: Pfizer Director LOSES IT When Confronted By Veritas

TikTok CEO To Face Congress: What Will He Say?